David Grainger is a partner at medicxi, a European life sciences-oriented venture capital firm[1] and chief executive officer of Methuselah Health Ltd., a drug development company doing proteomics research in the longevity space.
[5] Reared in England, Grainger graduated with degree in Natural Sciences (Biochemistry) from Cambridge University in 1989, and a PhD in Vascular Cell Biology from the same institution in 1992.
[6] After receiving his PhD, Grainger undertook post-doctoral research in the British Heart Foundation Smooth Muscle Cell laboratory at Cambridge University.
[11] While at Cambridge University, Grainger founded life sciences companies including FingerPrint Diagnostics (2001),[12] and Funxional Therapeutics (2005).
[15] Grainger joined Index Ventures in 2012,[16] and a blogger on topics related to the pharmaceutical industry under the pen name “DrugBaron”.